ProMining Therapeutics
Drug Discovery Platform for Novel Oral Drugs
Company Overview
Snapshot
Founded in November 2011 by Iris Alroy, Ph.D., ProMining Therapeutics operates with over 18,000 employees. The company has secured funding from Pontifax for its drug discovery and development efforts. In December 2012, ProMining Therapeutics announced a collaboration with Roche on diabetes treatment.
Business overview
ProMining Therapeutics Ltd specializes in the discovery and development of novel oral, small-molecule drugs. The company focuses on treatments for cancer, inflammation, chronic pain, and cardiovascular and viral diseases. Its core technology, CavitIIRx, is a proprietary drug-discovery and development platform centered on SH3 domain-mediated protein-protein interactions, which are crucial in various disease mechanisms. ProMining Therapeutics leverages this platform to identify promising drug candidate molecules, build a pipeline of drugs, and accelerate the drug discovery process within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In December 2012, ProMining Therapeutics announced a strategic collaboration with Roche to develop treatments for diabetes. This partnership with a major pharmaceutical company like Roche signals significant external validation of ProMining's drug discovery platform and its potential to attract substantial industry interest for its therapeutic candidates.
Log in to access full profile ›Company Intelligence Q&A
- When was ProMining Therapeutics founded?
- ProMining Therapeutics was founded in November 2011.
- Who is a co-founder of ProMining Therapeutics?
- Iris Alroy, Ph.D. is a co-founder of ProMining Therapeutics.
- What is the primary focus of ProMining Therapeutics' drug discovery efforts?
- ProMining Therapeutics focuses on discovering and developing novel oral, small-molecule drugs for cancer, inflammation, chronic pain, and cardiovascular and viral diseases.
- What is CavitIIRx?
- CavitIIRx is ProMining Therapeutics' proprietary drug-discovery and development platform, which focuses on SH3 domain-mediated protein-protein interactions.
- Did ProMining Therapeutics engage in any significant collaborations?
- In December 2012, ProMining Therapeutics collaborated with Roche on diabetes treatment.